Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms
S. Kelliher, S. Gamba, L. Weiss, Z. Shen, M. Marchetti, F. Schieppati, C. Scaife, S. Madden, K. Bennett, A. Fortune, S. Maung, M. Fay, F. Ni Ainle, P. Maguire, A. Falanga, B. Kevane, A. Krishnan
Abstract
Patients with chronic Myeloproliferative Neoplasms (MPN) including polycythemia vera (PV) and essential thrombocythemia (ET) exhibit unique clinical features, such as a tendency toward thrombosis and hemorrhage, and risk of disease progression to secondary bone marrow fibrosis and/or acute leukemia. Although an increase in blood cell lineage counts (quantitative features) contribute to these morbid sequelae, the significant qualitative abnormalities of myeloid cells that contribute to vascular risk are not well understood. Here, we address this critical knowledge gap via a comprehensive and untargeted profiling of the platelet proteome in a large (n= 140) cohort of patients (from two independent sites) with an established diagnosis of PV and ET (and complement prior work on the MPN platelet transcriptome from a third site). We discover distinct MPN platelet protein expression and confirm key molecular impairments associated with proteostasis and thrombosis mechanisms of potential relevance to MPN pathology. Specifically, we validate expression of high-priority candidate markers from the platelet transcriptome at the platelet proteome (e.g., calreticulin (CALR), Fc gamma receptor (Fc{gamma}RIIA) and galectin-1 (LGALS1) pointing to their likely significance in the proinflammatory, prothrombotic and profibrotic phenotypes in patients with MPN. Together, our proteo-transcriptomic study identifies the peripherally-derived platelet molecular profile as a potential window into MPN pathophysiology and demonstrates the value of integrative multi-omic approaches in gaining a better understanding of the complex molecular dynamics of disease. HighlightsMPN patient platelet proteome identifies key pathobiological mediators of thrombosis and proteostasis. The MPN platelet proteomic profile validates our prior findings from the platelet transcriptome. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=134 SRC="FIGDIR/small/563619v2_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@1cb6290org.highwire.dtl.DTLVardef@1b3ec3eorg.highwire.dtl.DTLVardef@15b0c8eorg.highwire.dtl.DTLVardef@9575b2_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Plasma proteome screen of individuals with elevated blood counts to identify diagnostic signatures and biomarkers inherent to patients with myeloproliferative neoplasms
Xiangfu Zhong, Ingrid E. J. Lundahl, … Johanna S. Ungerstedt·bioRxiv·Aug 4, 2026
- Megakaryocytic proteomic signatures define myeloproliferative neoplasms
Indu Raman, Cavan Bennett, … Sukhdeep Spall·bioRxiv·Nov 2, 2026
- Increased bleeding and thrombosis in myeloproliferative neoplasms mediated through altered expression of inherited platelet disorder genes
Alan Mitchell, Mattia Frontini, … Anandi Krishnan·bioRxiv·May 23, 2023
- Platelets Outperform Leukocytes in Transcriptomic Liquid Biopsy Profiling of Myeloproliferative Neoplasms
Zhu Shen, Abhishek Sawalkar, … Anandi Krishnan·bioRxiv·Apr 1, 2026
- Platelet transcriptome yields progressive markers in chronic myeloproliferative neoplasms and identifies putative targets of therapy
Zhu Shen, Wenfei Du, … Anandi Krishnan·BloodPeer-reviewed·Nov 5, 2021
- Thrombo-inflammatory endothelial signatures in JAK2-mutated myeloproliferative neoplasms
Salma AS Abosabie, Alexandra Boye‐Doe, … Anish V. Sharda·bioRxiv·Feb 18, 2026